| 발표일자: |
2014년 4월 12일(토) ~ 4월 13일(일) |
| 발표번호: |
P(판넬)-094 |
| 발표장소: |
킨텍스 제2전시장 7B홀 |
|
|
| The Combined Treatment of Bevacizumab and Cyclosporin A(CsA) has Effects on Pterygial Tissues and Cells by reducing the MMP-3 and MMP-13 Expression and the Migration |
| Cheil Eye Research Institute, Cheil Eye Hospital(1)
Department of Biology, College of Natural Sciences, Kyungpook National University(2) |
| Yong Il Kim(1), Yeoun-Hee Kim(1), Sun-Hee Kang(2), Jae-Chang Jung(2), Kyoo Won Lee(1), Young Jeung Park(1) |
|
목적 : To investigate the effects of Bevacizumab or/and Cyclosporin A(CsA) through the regulation of matrix metalloproteinase MMP-3 and MMP-13 expression on the pterygial tissues and cells.
방법 : Pterygial and normal conjunctival tissue of 20 patients were analyzed. Cell migration was captured by using phase contrast microscope in 24h and 48h. After injection of 2.5mg/0.1ml bevacizumab, 7days later, injected-tissues were investigated changed protein levels by Western blot and immunostaining. Human pterygial fibroblast cells and explanted tissues were exposed to CsA concentrations of 1μg/ml and 100μg/ml for 3 or 10minutes and/or bevacizumab 1μg/ml with serum depletion DMEM/F-12 media for 48h. Changes in expression of MMP-3 and MMP-13 of fibroblast after the stimulation were studied.
결과 : MMP-3 and MMP-13 expression in pterygium tissues were greater than those of normal conjunctiva. In cultured pterygial cells and explanted tissues, cell migration were significantly inhibited by concentration of 1 μM MMPs inhibitor. Bevacizumab-injected pterygium tissues were significantly reduced MMP-3 and MMP-13 expression. Interestingly, pre-exposed pterygial fibroblast and tissues with CsA and followed by bevacizumab treatment blocked the cell migration and MMP-3 and MMP-13 expression (P<0.01), significantly higher in explanted pterygial tissues and cultured pterygial cells.
결론 : Our results suggested high expression of MMPs induced proliferation and migration of pterygial fibroblast and explanted tissues. And, expression of MMPs was down-regulated by bevacizumab or CsA treatment. Moreover, combined treatment of CsA and bevacizumab was more effective in inhibition of MMPs expression. These finding also provide therapeutic potential for pterygium progression.
|
| |